Computational Modeling of Drugs Against Alzheimer's Disease

2. Auflage 2023
ISBN: 978-1-0716-3313-7
Verlag: Springer US

Buch, Englisch, 493 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 953 g

Reihe: Neuromethods

This second edition volume expands on the previous edition with updated descriptions on different computational methods encompassing ligand-based, structure-based, and combined approaches with their recent applications in anti-Alzheimer drug design. Different background topics like recent advancements in research on the development of novel therapies and their implications in the treatment of Alzheimer’s Disease (AD) have also been covered for completeness. Special topics like basic information science methods for insight into neurodegenerative pathogenesis, drug repositioning and network pharmacology, and online tools to predict ADMET behavior with reference to anti-Alzheimer drug development have also been included. In the Neuromethods series style, chapter include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.
Cutting-edge and thorough, Computational Modeling of Drugs Against Alzheimer’s Disease, Second Edition is a valuable resource for all researchers and scientists interested in learning more about this important and developing field.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Roy, Kunal

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft

Inhaltsverzeichnis

Recent Progress in the Treatment Strategies of Alzheimer’s Disease.- Understanding the Mechanisms of Amyloid Beta (Aß) Aggregation by Computational Modeling.- Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agents.- Modeling of BACE-1 Inhibitors as Anti-Alzheimer’s Agents.- Computational Modeling of Kinase Inhibitors as Anti-Alzheimer Agents.- Computer-Assisted Drug Design: A Toolbox for Novel Tau Kinase Inhibitors and Its Implications in Alzheimer’s Disease.- Computational Modeling Approaches in Search of Anti-Alzheimer Agents: Case Studies of Phosphodiesterase Inhibitors.- Recent Advances in Computational Modeling of Multi-Targeting Inhibitors as Anti-Alzheimer Agents.- Computational Modeling of PET and SPECT Imaging Agents as Diagnostics for Alzheimer’s Disease.- Computational Modeling of DYRK1A Inhibitors as Potential Anti-Alzheimer Agents.- Computational Modeling of MAO Inhibitors as Anti-Alzheimer Agents.- Computational Modeling of Phosphodiesterase Inhibitors as Anti-Alzheimer Agents.- Computational Methods for the Design and Development of Glutaminyl Cyclase Inhibitors in Alzheimer’s Disease.- Basic Information Science Methods for Insight into Neurodegenerative Pathogenesis.- Network Pharmacology for Drug Repositioning in Anti-Alzheimer's Drug Development.- Web Services for the Prediction of ADMET Parameters Relevant to the Design of Neuroprotective Drugs.